公开(公告)号：EP3207938A3

公开(公告)日：2017-11-01

申请号：EP17163638.4

申请日：2013-03-11

申请人： Medimmune, LLC ,  Medimmune Limited

发明人： MINTER, Ralph ,  DOUTHWAITE, Julie ,  MOISAN, Jacques ,  BOWEN, Michael ,  RUST, Steven ,  PRIVESENTZEV, Cyril

IPC分类号： A61K38/16 ,  C07K1/00

摘要： Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.

摘要翻译： 细胞毒性T淋巴细胞抗原4（CTLA-4）的变体具有高亲和力，效力和稳定性。 用于皮下或静脉内给药的高浓度CTLA-4变体的制剂，例如， 每月或更少的剂量间隔。 使用CTLA-4变体治疗类风湿性关节炎和其他炎性疾病。 CTLA-4与IgG Fc的融合具有改善的稳定性和更长的体内半衰期。

公开(公告)号：EP3207938A2

公开(公告)日：2017-08-23

申请号：EP17163638.4

申请日：2013-03-11

申请人： Medimmune, LLC ,  Medimmune Limited

发明人： MINTER, Ralph ,  DOUTHWAITE, Julie ,  MOISAN, Jacques ,  BOWEN, Michael ,  RUST, Steven ,  PRIVESENTZEV, Cyril

IPC分类号： A61K38/16 ,  C07K1/00

摘要： Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.

公开(公告)号：EP2863936A1

公开(公告)日：2015-04-29

申请号：EP13787673.6

申请日：2013-03-11

申请人： MedImmune, LLC ,  Medimmune Limited

发明人： MINTER, Ralph ,  DOUTHWAITE, Julie ,  MOISAN, Jacques ,  BOWEN, Michael ,  RUST, Steve ,  PRIVEZENTZEV, Cyril

IPC分类号： A61K38/16 ,  C07K1/00

CPC分类号： C07K14/70521 ,  A61K38/00 ,  C07K2319/30

摘要： Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.

公开(公告)号：EP3207938B1

公开(公告)日：2019-12-25

申请号：EP17163638.4

申请日：2013-03-11

申请人： MedImmune Limited

发明人： MINTER, Ralph ,  DOUTHWAITE, Julie ,  MOISAN, Jacques ,  BOWEN, Michael ,  RUST, Steven ,  PRIVESENTZEV, Cyril

IPC分类号： C07K14/705 ,  A61K38/00